Urologic view in the management of genitourinary syndrome of menopause

References

• Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. J Am Med Assoc. 1999;281(6):537–545.
   PubMed Web of Science ®Google Scholar
• Batra SC, Iosif CS. Progesterone receptors in the female lower urinary tract. J Urol. 1987;138(5):1301–1304.
   PubMed Web of Science ®Google Scholar
• Ho MH, Bhatia NN, Bhasin S. Anabolic effects of androgens on muscles of female pelvic floor and lower urinary tract. Curr Opin Obstet Gynecol. 2004;16(5):405–409.
   PubMed Web of Science ®Google Scholar
• Iosif CS, Batra S, Ek A, et al. Estrogen receptors in the human female lower urinary tract. Am J Obstet Gynecol. 1981;141(7):817–820.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg A, Rosen J, Gustafsson SA, et al. Cytosol estrogen receptors in the urogenital tissues in stress–incontinent women. Acta Obstet Gynecol Scand. 1981;60(6):585–586.
   PubMed Web of Science ®Google Scholar
• Tan O, Bradshaw K, Carr BR. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. Menopause. 2012;19(1):109–117.
   PubMed Web of Science ®Google Scholar
• Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology. 2003;62(4 Suppl 1):45–51.
   PubMed Web of Science ®Google Scholar
• Lüthje P, Brauner H, Ramos NL, et al. Estrogen supports urothelial defense mechanisms. Sci Transl Med. 2013;5(190):190ra80.
   PubMed Web of Science ®Google Scholar
• Matsubara S, Okada H, Shirakawa T, et al. Estrogen levels influence beta-3-adrenoceptor-mediated relaxation of the female rat detrusor muscle. Urology. 2002;59(4):621–625.
   PubMed Web of Science ®Google Scholar
• Gandhi J, Chen A, Dagur G, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016;215(6):704–711.
   PubMed Web of Science ®Google Scholar
• Elliott RA, Castleden CM, Miodrag A, et al. The direct effects of diethylstilboestrol and nifedipine on the contractile responses of isolated human and rat detrusor muscles. Eur J Clin Pharmacol. 1992;43(2):149–155.
   PubMed Web of Science ®Google Scholar
• Batra S, Andersson KE. Oestrogen-induced changes in muscarinic receptor density and contractile responses in the female rabbit urinary bladder. Acta Physiol Scand. 1989;137(1):135–141.
   PubMedGoogle Scholar
• Aikawa K, Sugino T, Matsumoto S, et al. The effect of ovariectomy and estradiol on rabbit bladder smooth muscle contraction and morphology. J Urol. 2003;170(2 Pt 1):634–637.
   PubMed Web of Science ®Google Scholar
• Escobar C, Rosenblum N. Vaginal estrogen—what a urologist should know. Urology. [Internet]. 2021;151:37–43.
   PubMed Web of Science ®Google Scholar
• Shenfeld OZ, McCammon KA, Blackmore PF, et al. Rapid effects of estrogen and progesterone on tone and spontaneous rhythmic contractions of the rabbit bladder. Urol Res. 1999;27(5):386–392.
   PubMedGoogle Scholar
• Fantl JA, Wyman JF, Anderson RL, et al. Postmenopausal urinary incontinence: comparison between non-estrogen-supplemented and estrogen-supplemented women. Obstet Gynecol. 1988;71(6 Pt 1):823–828.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lose G, McClish D, et al. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand. 2004;83(10):892–897.
   PubMed Web of Science ®Google Scholar
• Iosif CS, Bekassy Z. Prevalence of genito-urinary symptoms in the late menopause. Acta Obstet Gynecol Scand. 1984;63(3):257–260.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass MLS. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and the North American menopause society. Climacteric. 2014;17(5):557–563.
   PubMed Web of Science ®Google Scholar
• Mili N, Paschou SA, Armeni A, et al. Genitourinary syndrome of menopause: a systematic review on prevalence and treatment. Menopause. 2021;28(6):706–716.
   PubMed Web of Science ®Google Scholar
• Cody JD, Jacobs ML, Richardson K, et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012;2012: CD001405.
   Google Scholar
• Eriksen PS, Rasmussen H. Low-dose 17β-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol. 1992;44(2):137–144.
   PubMed Web of Science ®Google Scholar
• Nelken RS, Özel BZ, Leegant AR, et al. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause. 2011;18(9):962–966.
   PubMed Web of Science ®Google Scholar
• Tseng L-H, Wang AC, Chang Y-L, et al. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol Urodyn. 2009;28(1):47–51.
   PubMed Web of Science ®Google Scholar
• Simon JA, Goldstein I, Kim NN, et al. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Menopause. 2018;25(7):837–847.
   PubMed Web of Science ®Google Scholar
• Labrie F, Derogatis L, Archer DF, et al. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med. 2015;12(12):2401–2412.
   PubMed Web of Science ®Google Scholar
• Collà Ruvolo C, Gabrielli O, Formisano C, et al. Prasterone in the treatment of mild to moderate urge incontinence: an observational study. Menopause. 2022;29(8):957–962.
   PubMed Web of Science ®Google Scholar
• Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293(8):935–948.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Rekers H, Tapp A, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas. 1993;18(1):47–53.
   PubMedGoogle Scholar
• Kagan R, Williams RS, Pan K, et al. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause. 2010;17(2):281–289.
   PubMed Web of Science ®Google Scholar
• FDA Approves Osphena (ospemifene) for Moderate to Severe Vaginal Dryness Due to Menopause [Internet]. Drugs.com. Available from: https://www.drugs.com/newdrugs/fda-approves-osphena-ospemifene-moderate-severe-vaginal-dryness-due-menopause-4910.html.
   Google Scholar
• Schiavi MC, Sciuga V, Giannini A, et al. Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: Improvement of sexuality? Gynecol Endocrinol. 2018;34(8):666–669.
   PubMed Web of Science ®Google Scholar
• Novara L, Sgro LG, Mancarella M, et al. Potential effectiveness of Ospemifene on Detrusor Overactivity in patients with vaginal atrophy. Maturitas. 2020;138:58–61.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Zullo MA, Faiano P, et al. Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms. Gynecol Endocrinol. 2017;33(12):942–945.
   PubMed Web of Science ®Google Scholar
• Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014;17(4):363–369.
   PubMed Web of Science ®Google Scholar
• Perino A, Cucinella G, Gugliotta S, et al. Is vaginal fractional CO2 laser treatment effective in improving overactive bladder symptoms in post-menopausal patients? Preliminary results. Eur Rev Med Pharmacol Sci. 2016;20(12):2491–2497.
   PubMed Web of Science ®Google Scholar
• Alsulihem A, Corcos J. The use of vaginal lasers in the treatment of urinary incontinence and overactive bladder, systematic review. Int Urogynecol J. 2021;32(3):553–572.
   PubMed Web of Science ®Google Scholar
• Long C-Y, Lin K-L, Lee Y-C, et al. Therapeutic effects of low intensity extracorporeal low energy shock wave therapy (LiESWT) on stress urinary incontinence. Sci Rep. 2020;10(1):5818.
   PubMed Web of Science ®Google Scholar
• Kun-Ling L, Jian-He L, Chueh K-S, et al. Low-intensity extracorporeal shock wave therapy promotes bladder regeneration and improves overactive bladder induced by ovarian hormone deficiency from rat animal model to human clinical trial. Int J Mol Sci. 2021;22(17):92961.
   PubMed Web of Science ®Google Scholar
• Valerie E, Gilchrist BF, Frischer J, et al. Diagnosis and treatment of urethral prolapse in children. Urology. 1999;54(6):1082–1084.
   PubMed Web of Science ®Google Scholar
• Lowe FC, Hill GS, Jeffs RD, et al. Urethral prolapse in children: insights into etiology and management. J Urol. 1986;135(1):100–103.
   PubMed Web of Science ®Google Scholar
• Abouzeid H, Shergill IS, Al-Samarrai M. Successful medical treatment of advanced urethral prolapse. J Obstet Gynaecol. 2007;27(6):634–635.
   PubMedGoogle Scholar
• Rudin JE, Geldt VG, Alecseev EB. Prolapse of urethral mucosa in white female children: experience with 58 cases. J Pediatr Surg. 1997;32(3):423–425.
   PubMed Web of Science ®Google Scholar
• Fletcher SG, Lemack GE. Benign masses of the female periurethral tissues and anterior vaginal wall. Curr Urol Rep. 2008;9(5):389–396.
   PubMedGoogle Scholar
• Young RH, Oliva E, Garcia JA, et al. Urethral caruncle with atypical stromal cells simulating lymphoma or sarcoma–a distinctive pseudoneoplastic lesion of females. A report of six cases. Am J Surg Pathol. 1996;20(10):1190–1195.
   PubMed Web of Science ®Google Scholar
• Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol. 2019;202(2):282–289.
   PubMed Web of Science ®Google Scholar
• Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the infectious diseases society of Americaa. Clin Infect Dis. 2019;68(10):e83–e110.
   PubMed Web of Science ®Google Scholar
• Werner NL, Hecker MT, Sethi AK, et al. Unnecessary use of fluoroquinolone antibiotics in hospitalized patients. BMC Infect Dis. 2011;11:187.
   PubMed Web of Science ®Google Scholar
• Cai T, Nesi G, Mazzoli S, et al. Asymptomatic bacteriuria treatment is associated with a higher prevalence of antibiotic resistant strains in women with urinary tract infections. Clin Infect Dis. 2015;61(11):civ696.
   Web of Science ®Google Scholar
• Jung C, Brubaker L. The etiology and management of recurrent urinary tract infections in postmenopausal women. Climacteric. 2019;22(3):242–249.
   PubMed Web of Science ®Google Scholar
• Foxman B, Barlow R, D’Arcy H, et al. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000;10(8):509–515.
   PubMed Web of Science ®Google Scholar
• Perrotta C, Aznar M, Mejia R, et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008;(2):CD005131.
   PubMed Web of Science ®Google Scholar
• Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124(6):1147–1156.
   PubMed Web of Science ®Google Scholar
• Rubin R, Moyneur E, Tjoa ML, et al. Mp30-15 Prevalence of urinary tract infections in women with genitourinary syndrome of menopause and the impact of vaginal prasterone on urinary tract infections. J Urol. 2020;203:e443–e444.
   Web of Science ®Google Scholar
• Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: How important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151–161.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Use and procurement of additional lubricants for male and female condoms: WHO/UNFPA/FHI360 advisory note. Geneva: WHO; 2012.
   Google Scholar